About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Meet the Cure Team Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Cure Symposium Calendar

Michele Cleary, Ph.D.

Michele Cleary, Ph.D., is a Vice President of Academic Outreach, Deerfield Discovery and Development, and joined the Firm in 2021. Prior to Deerfield, Dr. Cleary served for four years as the Chief Executive Officer of The Mark Foundation for Cancer Research. Prior to The Mark Foundation, she spent two years at Bristol Myers Squibb as Vice President, Clinical Translational Technologies and Operations. Before Bristol Myers Squibb, she worked at Merck and Co., Inc. for thirteen years in various positions, most recently, as Executive Director, Genetics & Pharmacogenomics. Dr. Cleary holds a B.S. in Natural Sciences from the Catholic University of America and a Ph.D. in Molecular Microbiology and Genetics from Stony Brook University School of Medicine. She trained as a graduate student at Cold Spring Harbor Laboratory and a post-doctoral fellow at Princeton University.